|
20 Sep 2025 |
CCL Products
|
Consensus Share Price Target
|
886.05 |
951.78 |
- |
7.42 |
buy
|
|
|
|
|
08 Aug 2025
|
CCL Products
|
Keynote Capitals Ltd
|
886.05
|
1203.00
|
864.35
(2.51%)
|
35.77 |
Buy
|
|
|
Quarterly Update Q1FY26
|
|
07 Aug 2025
|
CCL Products
|
IDBI Capital
|
886.05
|
849.00
|
862.65
(2.71%)
|
Target met |
Hold
|
|
|
CCL Products Q1FY26 profitability was below our expectations. Sales grew 37% YoY to Rs10.7bn, driven by 9-10% YoY volume growth and 27-28% YoY increase in realization due to improved coffee blends. Gross margin contracted by 543bps YoY to 32.6%, driven by higher input cost. Consequently, EBITDA margin contracted by 178bps YoY to 15.1%. EBITDA grew 22% YoY to Rs1.6bn, driven by a favorable product mix in B2B and growth in the B2C category. PAT increased by 1% YoY to Rs724mn. CCL maintained its volume and EBITDA growth guidance of 10-20% and 15-20%, respectively. Management expects some price...
|
|
07 Aug 2025
|
CCL Products
|
Axis Direct
|
886.05
|
970.00
|
862.65
(2.71%)
|
9.47 |
Buy
|
|
|
With a 12% upside from the CMP, we maintain our BUY rating on the stock.
|
|
07 May 2025
|
CCL Products
|
Keynote Capitals Ltd
|
886.05
|
1126.00
|
772.60
(14.68%)
|
27.08 |
Buy
|
|
|
Quarterly Update Q4FY25
|
|
07 May 2025
|
CCL Products
|
Axis Direct
|
886.05
|
800.00
|
772.60
(14.68%)
|
Target met |
Buy
|
|
|
With a 15% upside from the CMP, we maintain our BUY rating on the stock
|
|
06 May 2025
|
CCL Products
|
IDBI Capital
|
886.05
|
738.00
|
772.60
(14.68%)
|
Target met |
Hold
|
|
|
|
|
07 Feb 2025
|
CCL Products
|
IDBI Capital
|
886.05
|
698.00
|
654.35
(35.41%)
|
Target met |
Hold
|
|
|
|
|
07 Feb 2025
|
CCL Products
|
Keynote Capitals Ltd
|
886.05
|
1146.00
|
654.35
(35.41%)
|
29.34 |
Buy
|
|
|
Quarterly Update Q3FY25
|
|
07 Feb 2025
|
CCL Products
|
Axis Direct
|
886.05
|
730.00
|
654.35
(35.41%)
|
Target met |
Buy
|
|
|
With a 13% upside from the CMP, we maintain our BUY rating on the stock.
|
|
28 Jan 2025
|
CCL Products
|
CD Equisearch
|
886.05
|
681.00
|
599.45
(47.81%)
|
Target met |
Accumulate
|
|
|
|
|
11 Nov 2024
|
CCL Products
|
Keynote Capitals Ltd
|
886.05
|
1222.00
|
713.05
(24.26%)
|
37.92 |
Buy
|
|
|
Quarterly Update Q2FY25
|
|
11 Nov 2024
|
CCL Products
|
BP Wealth
|
886.05
|
|
713.05
(24.26%)
|
|
Results Update
|
|
|
|
|
07 Nov 2024
|
CCL Products
|
IDBI Capital
|
886.05
|
734.00
|
691.70
(28.10%)
|
Target met |
Hold
|
|
|
|
|
07 Nov 2024
|
CCL Products
|
Axis Direct
|
886.05
|
820.00
|
701.40
(26.33%)
|
Target met |
Buy
|
|
|
With a 14% upside from the CMP, we maintain our BUY rating on the stock.
|
|
09 Sep 2024
|
CCL Products
|
Keynote Capitals Ltd
|
886.05
|
1221.00
|
747.05
(18.61%)
|
|
Buy
|
|
|
Initiating Coverage Report
|
|
09 Aug 2024
|
CCL Products
|
Axis Direct
|
886.05
|
760.00
|
659.85
(34.28%)
|
Target met |
Buy
|
|
|
With a 15% upside from the CMP, we maintain our BUY rating on the stock.
|
|
14 May 2024
|
CCL Products
|
Axis Direct
|
886.05
|
670.00
|
563.40
(57.27%)
|
Target met |
Buy
|
|
|
With a 17% upside from the CMP, we maintain our BUY rating on the stock.
|
|
14 May 2024
|
CCL Products
|
IDBI Capital
|
886.05
|
582.00
|
563.40
(57.27%)
|
Target met |
Hold
|
|
|
|
|
30 Mar 2024
|
CCL Products
|
CD Equisearch
|
886.05
|
645.00
|
586.30
(51.13%)
|
Target met |
Hold
|
|
|
|
|
07 Feb 2024
|
CCL Products
|
Axis Direct
|
886.05
|
720.00
|
667.35
(32.77%)
|
Target met |
Buy
|
|
|
With a 12% upside from the CMP, we maintain our BUY rating on the stock.
|